Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.

about

Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma.

P2860

Q44962377-3A068A29-A4FB-49E7-9040-D359DD94DC87 Q53091304-0B6367E9-EB90-4F0A-851E-EE2567785CBE

P2860

Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.

Item

http://www.wikidata.org/entity/Q38065298

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.

@en

type

Item

label

Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.

@en

prefLabel

Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.

@en

P1476

Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis

@en

P2093

Claire Borie

http://www.w3.org/2001/XMLSchema#string

Ismail Elalamy

http://www.w3.org/2001/XMLSchema#string

Jordan Gauthier

http://www.w3.org/2001/XMLSchema#string

Marie Pierre Noel

http://www.w3.org/2001/XMLSchema#string

Salomon Manier

http://www.w3.org/2001/XMLSchema#string

Xavier Leleu

http://www.w3.org/2001/XMLSchema#string

P2860

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

Aspirin in the prevention and treatment of venous thromboembolism

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

P304

617-26; quiz 627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1586/EHM.12.52

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eileen M Boyle

Guillemette Fouquet

Thierry Facon

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233874674

http://www.w3.org/2001/XMLSchema#string

P698

23216532

http://www.w3.org/2001/XMLSchema#string

P921

thrombosis

Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.

about

P2860

P2860

Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921